Encouraging prostate cancer screening in Black men
Official title: Cleveland African American Prostate Cancer Project: Equivalence of Passive Navigation, Active Navigation, and Community-based Screening for Completion of Prostate Cancer Screening
Run by Case Comprehensive Cancer Center · NCT05469269 · Data updated 2026-11-12
This study is testing different ways to encourage Black men aged 40 and older to get prostate cancer screenings in local barbershops in Cleveland.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years and up |
| Sex | Men only |
| Enrollment | 800 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | June 9, 2023 |
| Main results expected | October 28, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT05469269 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Black or African American men aged 40 and older who have not had a PSA test in the past year.
✕Probably not a fit
Patients who have previously been diagnosed with prostate cancer or have undergone a prostatectomy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research aims to test different strategies to increase prostate cancer screening among Black or African American men aged 40 and older. The study evaluates three approaches: education with passive navigation, education with active navigation, and education combined with community outreach. The primary goal is to assess the completion of prostate-specific antigen (PSA) tests, with follow-up evaluations on participants' experiences and knowledge regarding prostate cancer. The study takes place in local barbershops in Cleveland, Ohio, to engage the community effectively.
Why it matters
Potential benefit: If successful, this study could significantly increase prostate cancer screening rates among Black men, leading to earlier detection and better outcomes.
How similar studies have gone: Other studies have shown success in using community-based approaches to improve cancer screening rates, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥40 years old * Self-identify as Black or African American * Have a prostate gland (includes biological males, transwomen) * PSA-naïve or has not received a PSA test in the past 12 months * Has not had a previous prostate cancer diagnosis * English speaking * Ability to consent to study Exclusion Criteria: * Individuals who have had a prostatectomy
Where it's running
-
Barbershops Local to Cleveland
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Erika Trapl, PhD — Case Comprehensive Cancer Center
- Study coordinator: Erika Trapl, PhD
- Email: CAAPP@case.edu
- Phone: 216-368-8772
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.